Trial Profile
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms ORBIT2
- Sponsors Shire; Takeda
- 08 Mar 2023 Results (n=514) assessing the safety of an investigational formulation of budesonide (budesonide oral suspension; BOS) from six trials (SHP621-101 (no clinical trials registration number), MPI 101-01 (NCT00762073), MPI 101-06 (NCT01642212), SHP621-301 (NCT02605837), SHP621-302 (NCT02736409) and SHP621-303 (NCT03245840)), published in the Alimentary Pharmacology and Therapeutics.
- 21 Dec 2021 According to a Takeda media release, the FDA recommended an additional clinical study in order to help resolve FDA feedback. The company is assessing the details of the CRL and evaluating a regulatory path forward.
- 21 Dec 2021 According to a Takeda media release, the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 for the treatment of eosinophilic esophagitis (EoE). The CRL indicates the FDA has completed its review and determined that it cannot be approved in its present form.